Momenta Provides Year-End 2019 Update and 2020 Outlook

-- Interim Phase 1 / 2 data of M254 in ITP supports expansion of lower dose cohorts; additional data expected Q2; plan to initiate Phase 2 study in CIDP – -- Nipocalimab (M281) MG study 80% enrolled;...